Plasminogen activators and plasminogen activator inhibitors: biochemical aspects
- PMID: 7549064
- DOI: 10.1016/s0950-3536(05)80269-0
Plasminogen activators and plasminogen activator inhibitors: biochemical aspects
Abstract
Although this chapter does not represent a historical review, it will be clear how the biochemistry of t-PA, u-PA, PAI-1 and PAI-2 has evolved and where we stand in 1994. While the functional activities of the proteins were recognized at least three to four decades ago, highly purified preparations became available around 1980. In the mid-eighties the cDNAs of the proteins were cloned, representing a major breakthrough in the biochemistry of the four proteins. Amino acid sequences were derived from the nucleotide sequences, homologies with other proteins were recognized and larger amounts of (recombinant) proteins became available for research. In addition, mutant proteins were prepared by recombinant DNA technology, enabling investigation of structure-function relationships. This report is mainly based on the latter studies. Detailed information about three-dimensional structures of the proteins and the mode of interaction with other macromolecules is still lacking. To obtain this information will be the goal for biochemists in the coming years.
Similar articles
-
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211. J Clin Invest. 1989. PMID: 2503541 Free PMC article.
-
Quantitative evaluation of the influence of ovarian steroids on plasminogen activators and inhibitors in human endometrial cells and trophoblasts.Thromb Res. 2002 Nov 25;108(4):235-44. doi: 10.1016/s0049-3848(03)00029-x. Thromb Res. 2002. PMID: 12617987
-
Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.Protein Eng. 1995 Dec;8(12):1295-1302. doi: 10.1093/protein/8.12.1295. Protein Eng. 1995. PMID: 8869642
-
Fibrin-specific fibrinolysis.Ann N Y Acad Sci. 1992 Dec 4;667:259-71. doi: 10.1111/j.1749-6632.1992.tb51623.x. Ann N Y Acad Sci. 1992. PMID: 1285022 Review. No abstract available.
-
[Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks].Ginekol Pol. 2004 Dec;75(12):971-8. Ginekol Pol. 2004. PMID: 15751221 Review. Polish.
Cited by
-
Three-dimensional structure of fibrolase, the fibrinolytic enzyme from southern copperhead venom, modeled from the X-ray structure of adamalysin II and atrolysin C.AAPS PharmSci. 2001;3(2):E16. doi: 10.1208/ps030216. AAPS PharmSci. 2001. PMID: 11741267 Free PMC article.
-
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.Br J Cancer. 1999 Apr;80(1-2):286-94. doi: 10.1038/sj.bjc.6690353. Br J Cancer. 1999. PMID: 10390010 Free PMC article.
-
Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis.J Clin Med. 2023 Jan 29;12(3):1035. doi: 10.3390/jcm12031035. J Clin Med. 2023. PMID: 36769682 Free PMC article.
-
Lifestyle, fibrinolysis and lipids.Pharm World Sci. 1997 Apr;19(2):82-8. doi: 10.1023/a:1008630308694. Pharm World Sci. 1997. PMID: 9151346 Review.
-
Reduced gingival fluid flow: a peripheral marker of the pharmacological effect of roquinimex.Inflammopharmacology. 2003;11(3):267-76. doi: 10.1163/156856003322315613. Inflammopharmacology. 2003. PMID: 15035809
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous